Craig McKnight, MD
Obstetrics & Gynecology · Niantic, CTNPI 1952445272
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $3,150 of the $4,922 with a category attached, or 64.0%. Minerva Surgical, Inc accounts for 67.0% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2020 at $3,300 and has fallen 90.0% since, to $330 in 2025. Among obstetrics & gynecology clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 54 payments — averaging $91.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Minerva Surgical, Inc$3K
- Coloplast$364
- Astellas Pharma US Inc$251
- Pfizer$173
- Saluda Medical Americas, Inc.$152
- Boston Scientific$117
- plus $565 from 12 others
What the payments were for
- Speaking & faculty fees$3,15064%
- Food & beverage$1,67434%
- Education$982%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Minerva Surgical, Inc | 6 | $3,300 |
| Coloplast | 4 | $364 |
| Astellas Pharma US Inc | 10 | $251 |
| Pfizer | 9 | $173 |
| Saluda Medical Americas, Inc. | 1 | $152 |
| Boston Scientific | 1 | $117 |
| MML US, Inc. | 1 | $110 |
| Amgen | 6 | $107 |
| Sumitomo Pharma America, Inc. | 5 | $91 |
| Abbott | 1 | $85 |
| AbbVie(2 entities) | 2 | $41 |
| Novo Nordisk | 2 | $30 |
| Daiichi Sankyo Inc. | 1 | $22 |
| Urovant Sciences Inc | 1 | $20 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $19 |
| Merck | 1 | $14 |
| Therapeuticsmd, Inc. | 1 | $14 |
| Exeltis, USA Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Minerva ES$3,258
- Genesys HTA$3,258
- SYMPHION$3,258
- Resectr$3,258
- Evoke$152
- SPEEDICATH$117
- WaveWriter Alpha Prime 16$117
- ReActiv8$110
How this compares
$4,922 in reported general payments places this provider in the 90th percentile of 605 obstetrics & gynecology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 60 | $62,287 |
| GemtesaVibegron | 31 | $38,802 |
| EstringEstradiol | 28 | $14,804 |
| Mirabegron ErMirabegron | 12 | $9,655 |
| YuvafemEstradiol | 40 | $8,630 |
| PremproEstrogen,con/M-Progest Acet | 24 | $7,795 |
| Estradiol | 68 | $7,354 |
| Tolterodine Tartrate ErTolterodine Tartrate | 63 | $7,341 |
| PremarinEstrogens, Conjugated | 12 | $6,556 |
| Ibandronate Sodium | 71 | $1,881 |
| Tolterodine Tartrate | 17 | $1,021 |
| Solifenacin Succinate | 13 | $505 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 13 | $124 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $251 | $62,28760 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $91 | $38,80231 claims |
| PfizerEstring, Prempro, Premarin | $173 | $29,15564 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 605 obstetrics & gynecology providers in Connecticut.
Other obstetrics & gynecology in Niantic
- Mary MinkinNew Haven$285K
- Alessandro SantinNew Haven$98K
- Frederick RauHartford$89K
- Peter AuerbachGroton$41K
- Shieva GhofranyStamford$33K
- Mark LeondiresNorwalk$31K
- Alan FineHartford$30K
- Sean FlahertyHamden$28K
- Adam SteinbergHartford$23K
- Sarp AkselStamford$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.